Nutex Health (NUTX)
(Delayed Data from NSDQ)
$10.10 USD
+2.20 (27.85%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $9.95 -0.15 (-1.48%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Nutex Health Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 248 | 219 | 19 | 2 | 1 |
Cost Of Goods | 213 | 206 | 15 | 1 | 1 |
Gross Profit | 35 | 13 | 4 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 67 | 420 | 13 | 6 | 7 |
Income After Depreciation & Amortization | -32 | -407 | -9 | -5 | -7 |
Non-Operating Income | 0 | -1 | 1 | 0 | 0 |
Interest Expense | 16 | 12 | 7 | 0 | 0 |
Pretax Income | -48 | -420 | -15 | -6 | -7 |
Income Taxes | -5 | 13 | -1 | 0 | 0 |
Minority Interest | 2 | -8 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -43 | -433 | -14 | -6 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -46 | -425 | -14 | -6 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -14 | -393 | -8 | -5 | -7 |
Depreciation & Amortization (Cash Flow) | 18 | 13 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -32 | -407 | -9 | -5 | -7 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.36 | 4.23 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -10.50 | -6.00 | NA | NA | NA |
Diluted Net EPS (GAAP) | -10.49 | -100.45 | -55.47 | -170.91 | -293.85 |
Fiscal Year end for Nutex Health Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 67.45 | 69.67 | 62.72 | 58.92 |
Cost Of Goods | NA | 57.30 | 56.46 | 55.66 | 49.28 |
Gross Profit | NA | 10.16 | 13.21 | 7.07 | 9.65 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.71 | 10.06 | 7.89 | 10.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.45 | 3.15 | -0.82 | -0.36 |
Non-Operating Income | NA | 2.84 | -0.33 | 0.05 | 0.12 |
Interest Expense | NA | 4.44 | 4.24 | 4.10 | 4.84 |
Pretax Income | NA | -0.15 | -30.71 | -4.87 | -5.08 |
Income Taxes | NA | 0.39 | -3.00 | -0.34 | -0.82 |
Minority Interest | NA | -0.18 | 3.91 | 1.02 | -0.79 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.54 | -27.71 | -4.52 | -4.27 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.36 | -31.62 | -5.54 | -3.48 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.64 | 4.22 | 3.70 | 4.38 |
Diluted EPS Before Non-Recurring Items | NA | -0.10 | -7.50 | -1.50 | -1.50 |
Diluted Net EPS (GAAP) | NA | -0.10 | -6.00 | -1.50 | -1.50 |